Lupin launches Vilfuro-G for COPD Management in India
Lupin Vilfuro-G is the only FDC that uniquely combines Vilanterol, Fluticasone Furoate and Glycopyrronium Bromide
Lupin Vilfuro-G is the only FDC that uniquely combines Vilanterol, Fluticasone Furoate and Glycopyrronium Bromide
First-in-class AKT inhibitor has potential to reshape treatment for breast cancer patients
This innovative solution comes as an answer to the industry-wide challenges of availability, cost, and dependencies linked to custom and proprietary hardware components
Evinova will operate as a separate health-tech business within AstraZeneca
Decision on EU marketing authorisation expected for momelotinib by early 2024
Gene therapy AB-1005 being developed to locally increase glial cell line-derived neurotrophic factor (GDNF) levels
This approval showcases Teva’s proven strengths in complex generic formulations development and device engineering
The countrywide initiative aims to spread awareness, educate the public & ensure that no one is left behind in the fight against respiratory diseases
Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone
Subscribe To Our Newsletter & Stay Updated